ACELYRIN(US:SLRN) Newsfilter·2024-06-05 11:00Core Insights - ACELYRIN, INC. announced positive results from its global Phase 2b/3 clinical trial of izokibep for psoriatic arthritis, which will be presented at the 2024 European Alliance of Associations for Rheumatology Congress [1] Company Overview - ACELYRIN, INC. is a late-stage clinical biopharma company based in Los Angeles, focused on developing transformative medicines, with operations also in the San Francisco Bay area [6] - The company has two late-stage clinical programs: izokibep for psoriatic arthritis and hidradenitis suppurativa, and lonigutamab for thyroid eye disease [6] Clinical Trial Details - The Phase 2b/3 clinical trial (NCT05623345) involved 351 adult patients with active psoriatic arthritis, randomized across four treatment arms [2] - Izokibep was administered subcutaneously at doses of 160 mg weekly, 160 mg every two weeks, and 80 mg every four weeks, compared to a placebo [2] Product Information - Izokibep is designed to inhibit IL-17A, a mechanism validated for treating psoriatic arthritis and other immune-mediated diseases [1][5] - The small protein therapeutic has a high potency and tight binding affinity, potentially allowing for robust tissue penetration and extended half-life due to its albumin binding domain [5] Disease Context - Psoriatic arthritis is a chronic immune-mediated inflammatory disease affecting approximately 30% of the 125 million people with psoriasis globally, highlighting a significant unmet need for effective therapies [4]